1. Home
  2. NTLA vs TMP Comparison

NTLA vs TMP Comparison

Compare NTLA & TMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTLA
  • TMP
  • Stock Information
  • Founded
  • NTLA 2014
  • TMP 1836
  • Country
  • NTLA United States
  • TMP United States
  • Employees
  • NTLA N/A
  • TMP N/A
  • Industry
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • TMP Major Banks
  • Sector
  • NTLA Health Care
  • TMP Finance
  • Exchange
  • NTLA Nasdaq
  • TMP Nasdaq
  • Market Cap
  • NTLA 710.1M
  • TMP 852.1M
  • IPO Year
  • NTLA 2016
  • TMP N/A
  • Fundamental
  • Price
  • NTLA $8.28
  • TMP $62.49
  • Analyst Decision
  • NTLA Buy
  • TMP Buy
  • Analyst Count
  • NTLA 19
  • TMP 2
  • Target Price
  • NTLA $38.47
  • TMP $69.00
  • AVG Volume (30 Days)
  • NTLA 3.1M
  • TMP 47.7K
  • Earning Date
  • NTLA 05-08-2025
  • TMP 04-25-2025
  • Dividend Yield
  • NTLA N/A
  • TMP 4.03%
  • EPS Growth
  • NTLA N/A
  • TMP 653.03
  • EPS
  • NTLA N/A
  • TMP 5.16
  • Revenue
  • NTLA $45,569,000.00
  • TMP $297,067,000.00
  • Revenue This Year
  • NTLA N/A
  • TMP $12.86
  • Revenue Next Year
  • NTLA N/A
  • TMP $7.68
  • P/E Ratio
  • NTLA N/A
  • TMP $11.94
  • Revenue Growth
  • NTLA N/A
  • TMP 35.84
  • 52 Week Low
  • NTLA $5.90
  • TMP $43.32
  • 52 Week High
  • NTLA $28.18
  • TMP $79.01
  • Technical
  • Relative Strength Index (RSI)
  • NTLA 51.86
  • TMP 59.39
  • Support Level
  • NTLA $7.21
  • TMP $60.24
  • Resistance Level
  • NTLA $9.27
  • TMP $62.19
  • Average True Range (ATR)
  • NTLA 0.65
  • TMP 1.74
  • MACD
  • NTLA 0.02
  • TMP 0.65
  • Stochastic Oscillator
  • NTLA 53.33
  • TMP 96.03

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

About TMP Tompkins Financial Corporation

Tompkins Financial Corp is a Financial Holding Company. It has three business segments, consisting of banking, insurance and wealth management. It offers various products and services, including commercial and consumer banking, leasing, trust and investment management, financial planning and wealth management, and insurance. Insurance is comprised of property and casualty insurance services and employee benefit consulting. Wealth management activities include the results of the company's trust, financial planning, and wealth management services. The company generates majority of its revenue from Banking segment.

Share on Social Networks: